ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 32

Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis

John M. Davis III1, Cynthia S. Crowson2, Keith L. Knutson3, Sara J. Achenbach4, Terry M. Therneau5, Eric L. Matteson6, Sherine E. Gabriel7 and Peter J. Wettstein8, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Immunology, Mayo Clinic, Jacksonville, FL, 4Mayo Clinic, Rochester, MN, 5Biostatistics, Mayo Clinic, Rochester, MN, 6Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 7Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 8Immunology, Mayo Clinic, Rochester, MN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cell targeting, cytokines, innate immunity and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Positive rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) identify a major rheumatoid arthritis (RA) subgroup, characterized by greater propensity to erosive joint damage and extra-articular disease manifestations as compared to seronegative patients. The purpose was to determine the associations between RF/ACPA and changes in functional immune response signatures over 5 years in patients with RA.

Methods:

A longitudinal analysis was performed of baseline and 5-year follow-up data from a prospective study of adult RA patients in a population-based incidence cohort. Data were available for 324 patients at baseline and for 155 patients at 5 years. Peripheral blood leukocytes (PBL) were freshly collected from patients and isolated by Ficoll density gradient centrifugation at both time-points. PBLs were stimulated at 37°C for 48 hrs under six separate conditions: anti-CD3/anti-CD28 monoclonal antibodies (CD3/CD28); phytohemagglutinin (PHA), staphylococcal enterotoxins A and B (SEA/SEB); phorbol myristate acetate and ionomycin (PMA); CpG oligonucleotides (CpG ODN2006); and medium alone. A panel of 17 cytokines and chemokines was analyzed using multiplexed immunoassays (Meso Scale Discovery). RF was measured using the nephelometry (CSL Behring), and ACPA was measured by Quanta Lite CCP3 IgG (Inova Diagnostics). Factor analysis of normalized data was performed using baseline data on 324 patients to make inferences about underlying cell types based on cytokine profiles. Among the 155 patients with follow-up, Spearman methods were used to assess correlations between RF and/or ACPA seropositivity and longitudinal changes in the factor scores for each stimulus, adjusting for age and sex.

Results:

A total of 109 (70%) of the 155 patients were seropositive at baseline (median age: 57.7 yrs; median disease duration: 9.7 yrs). RF/ACPA positively associated with CpG factor 1 (r = 0.28, p <.001), factor 2 (r = 0.21, p =.011), and factor 3 (r = 0.20, p =.015). Based on loadings >0.5, CpG factor 1 comprised IL-1β, G-CSF, TNF-α, MIP-1β, and IL-6; factor 2 comprised IFNγ, IL-2, and IL-13; and factor 3 comprised IL-12, and IL-5. Previous studies have shown that the type of CpG used in this study mainly activates B cells. Responses to medium alone paralleled those to CpG, as RF/ACPA positively correlated with medium alone factor 1 (r = 0.27, p <.001) and factor 3 (r = 0.29, p <.001) responses. Medium alone factor 1 comprised GM-CSF, MCP-1, IL-17A, IL-6, MIP-1β, TNF-α, and G-CSF; factor 3 comprised IL-1β and TNF-α. Based on this profile, multiple Toll-like receptor (TLR) ligands present in the medium fetal calf serum could have stimulated monocytes or other antigen presenting cells. In contrast, RF/ACPA negatively correlated with CD3/CD28-induced IL-5 (r = -0.21, p =.008), IL-17A (r = -0.22, p =.005), and GM-CSF (r = -0.20, p =.013).

Conclusion:

Our findings suggest that sustained stimulation of RF-containing immune complexes increases monocyte and B-cell activation states with increased expression of TLR. This could inform the development of functional assays for CpG and other TLR immune responses as predictors of response to B-cell directed therapy in RA.


Disclosure: J. M. Davis III, None; C. S. Crowson, None; K. L. Knutson, None; S. J. Achenbach, None; T. M. Therneau, None; E. L. Matteson, None; S. E. Gabriel, None; P. J. Wettstein, None.

To cite this abstract in AMA style:

Davis JM III, Crowson CS, Knutson KL, Achenbach SJ, Therneau TM, Matteson EL, Gabriel SE, Wettstein PJ. Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/longitudinal-associations-between-rheumatoid-factor-and-ex-vivo-cytokine-production-reveal-novel-mechanistic-insights-into-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-associations-between-rheumatoid-factor-and-ex-vivo-cytokine-production-reveal-novel-mechanistic-insights-into-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology